HomeCompareEKDHF vs MRK

EKDHF vs MRK: Dividend Comparison 2026

EKDHF yields 588.53% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EKDHF wins by $379.6K in total portfolio value
10 years
EKDHF
EKDHF
● Live price
588.53%
Share price
$0.34
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$436.3K
Annual income
$1,271.11
Full EKDHF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — EKDHF vs MRK

📍 EKDHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEKDHFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EKDHF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EKDHF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EKDHF
Annual income on $10K today (after 15% tax)
$50,025.01/yr
After 10yr DRIP, annual income (after tax)
$1,080.44/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $7,247.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EKDHF + MRK for your $10,000?

EKDHF: 50%MRK: 50%
100% MRK50/50100% EKDHF
Portfolio after 10yr
$246.6K
Annual income
$5,534.62/yr
Blended yield
2.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

EKDHF
No analyst data
Altman Z
9.2
Piotroski
7/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EKDHF buys
0
MRK buys
0
No recent congressional trades found for EKDHF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEKDHFMRK
Forward yield588.53%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%32.7%
Portfolio after 10y$436.3K$56.8K
Annual income after 10y$1,271.11$9,798.13
Total dividends collected$267.1K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EKDHF vs MRK ($10,000, DRIP)

YearEKDHF PortfolioEKDHF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$40,126$29,426.48$11,206$366.19+$28.9KEKDHF
2$98,112$55,176.68$12,650$502.35+$85.5KEKDHF
3$168,022$63,042.42$14,407$694.19+$153.6KEKDHF
4$230,234$50,450.31$16,585$967.82+$213.6KEKDHF
5$278,654$32,303.75$19,342$1,363.89+$259.3KEKDHF
6$316,430$18,269.86$22,913$1,947.19+$293.5KEKDHF
7$348,275$9,694.67$27,662$2,823.89+$320.6KEKDHF
8$377,640$4,986.13$34,159$4,173.35+$343.5KEKDHF
9$406,601$2,526.42$43,337$6,308.80+$363.3KEKDHF
10$436,334$1,271.11$56,776$9,798.13+$379.6KEKDHF

EKDHF vs MRK: Complete Analysis 2026

EKDHFStock

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company provides clinical chemical analyzers, such as Beta-hydroxybutyrate for monitoring ketosis; Glycated Albumin; Glycated Serum Protein; Nitro-tab Ketone tablets; and Procalcitonin marker for bacterial infection and sepsis, as well as reagents, calibrators, standards, and controls. Additionally, it offers RaPET Serology immunoassay kits; QuStick Strep A for Strep A infection treatment; Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and kits and other services related to COVID-19, as well as contract manufacturing solutions to third-party businesses and laboratory services. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

Full EKDHF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this EKDHF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EKDHF vs SCHDEKDHF vs JEPIEKDHF vs OEKDHF vs KOEKDHF vs MAINEKDHF vs JNJEKDHF vs ABBVEKDHF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.